FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1508581662> ?p ?o ?g. }

• W1508581662 endingPage "629" @default.
• W1508581662 startingPage "620" @default.
• W1508581662 abstract "What is known and Objective: Thrombolysis using intravenous tissue plasminogen activator (tPA) is the only available evidence-based treatment for acute ischaemic stroke; however, its current utilization is very low. Therefore, the aim of this article is to review the literature regarding the use of intravenous tPA for the treatment of acute ischaemic stroke. The review will also compare utilization rates of thrombolysis in different centres across the world and identify key reasons for the underutilization of thrombolysis in stroke. Methods: MEDLINE, EMBASE, International Pharmaceutical Abstracts (IPA) and Google Scholar were searched for relevant original articles, review papers and other publications over the publication period 1995–2012. Results and Discussion: The National Institute of Neurological Disorders and Stroke (NINDS) (1995, N = 624 patients) and ECASS III (2008, N = 821 patients) are two pivotal randomized controlled trials providing evidence for the use of intravenous tPA within 3 h or 3–4·5 h from stroke onset, respectively. Both trials have shown that tPA administration decreases disability at 90 days from stroke. Furthermore, a recent pooled analysis of randomized controlled trials (2010, N = 3670 patients) supports these results, highlighting that early stroke treatment is associated with better outcomes, especially when treatment is started within 90 min of stroke onset (but suggesting that the benefit could be afforded within a 4·5-h time window). Three major observational trials, STARS (2000, N = 389 patients), CASES (2005, N = 1135 patients) and SITS-MOST (2007, N = 6483 patients), have reported acceptable safety and efficacy in clinical practice. However, only a small proportion of acute ischaemic stroke patients receive tPA in clinical practice, because of the limited availability of tPA-utilizing sites and suboptimal use of tPA in sites where it is available. What is new and Conclusion: tPA reduces disability in stroke patients. Moreover, acceptable safety has been demonstrated in routine clinical practice. However, tPA is significantly underutilized, and specific efforts are needed to encourage appropriate implementation of the stroke treatment guidelines to optimize the use of this important therapy." @default.
• W1508581662 created "2016-06-24" @default.
• W1508581662 creator A5008776825 @default.
• W1508581662 creator A5081491821 @default.
• W1508581662 creator A5084998888 @default.
• W1508581662 date "2012-06-19" @default.
• W1508581662 modified "2023-09-24" @default.
• W1508581662 title "Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA)" @default.
• W1508581662 cites W1497225051 @default.
• W1508581662 cites W1851032411 @default.
• W1508581662 cites W188788053 @default.
• W1508581662 cites W1944845065 @default.
• W1508581662 cites W1974638135 @default.
• W1508581662 cites W1981323743 @default.
• W1508581662 cites W1987735300 @default.
• W1508581662 cites W1994867854 @default.
• W1508581662 cites W2001380059 @default.
• W1508581662 cites W2002318205 @default.
• W1508581662 cites W2002499827 @default.
• W1508581662 cites W2014335787 @default.
• W1508581662 cites W2018156750 @default.
• W1508581662 cites W2020821616 @default.
• W1508581662 cites W2022888515 @default.
• W1508581662 cites W2023552431 @default.
• W1508581662 cites W2029477045 @default.
• W1508581662 cites W2044967193 @default.
• W1508581662 cites W2048614158 @default.
• W1508581662 cites W2050683802 @default.
• W1508581662 cites W205495280 @default.
• W1508581662 cites W2056136317 @default.
• W1508581662 cites W2056414983 @default.
• W1508581662 cites W2059395281 @default.
• W1508581662 cites W2061599477 @default.
• W1508581662 cites W2071984852 @default.
• W1508581662 cites W2076085389 @default.
• W1508581662 cites W2076268153 @default.
• W1508581662 cites W2085963043 @default.
• W1508581662 cites W2093409635 @default.
• W1508581662 cites W2096231322 @default.
• W1508581662 cites W2096671972 @default.
• W1508581662 cites W2098032054 @default.
• W1508581662 cites W2098299329 @default.
• W1508581662 cites W2101104782 @default.
• W1508581662 cites W2102828922 @default.
• W1508581662 cites W2107272221 @default.
• W1508581662 cites W2109490919 @default.
• W1508581662 cites W2112328442 @default.
• W1508581662 cites W2119377192 @default.
• W1508581662 cites W2132305654 @default.
• W1508581662 cites W2133514192 @default.
• W1508581662 cites W2139899738 @default.
• W1508581662 cites W2141132646 @default.
• W1508581662 cites W2143000724 @default.
• W1508581662 cites W2144343313 @default.
• W1508581662 cites W2148750186 @default.
• W1508581662 cites W2152656156 @default.
• W1508581662 cites W2155758555 @default.
• W1508581662 cites W2157521317 @default.
• W1508581662 cites W2159233098 @default.
• W1508581662 cites W2161256482 @default.
• W1508581662 cites W2164763924 @default.
• W1508581662 cites W2166302161 @default.
• W1508581662 cites W2168683931 @default.
• W1508581662 cites W2292308933 @default.
• W1508581662 cites W2594075545 @default.
• W1508581662 cites W4210973470 @default.
• W1508581662 cites W4232875575 @default.
• W1508581662 cites W4292339830 @default.
• W1508581662 doi "https://doi.org/10.1111/j.1365-2710.2012.01366.x" @default.
• W1508581662 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22708668" @default.
• W1508581662 hasPublicationYear "2012" @default.
• W1508581662 type Work @default.
• W1508581662 sameAs 1508581662 @default.
• W1508581662 citedByCount "44" @default.
• W1508581662 countsByYear W15085816622012 @default.
• W1508581662 countsByYear W15085816622013 @default.
• W1508581662 countsByYear W15085816622014 @default.
• W1508581662 countsByYear W15085816622015 @default.
• W1508581662 countsByYear W15085816622016 @default.
• W1508581662 countsByYear W15085816622017 @default.
• W1508581662 countsByYear W15085816622018 @default.
• W1508581662 countsByYear W15085816622019 @default.
• W1508581662 countsByYear W15085816622020 @default.
• W1508581662 countsByYear W15085816622021 @default.
• W1508581662 countsByYear W15085816622022 @default.
• W1508581662 countsByYear W15085816622023 @default.
• W1508581662 crossrefType "journal-article" @default.
• W1508581662 hasAuthorship W1508581662A5008776825 @default.
• W1508581662 hasAuthorship W1508581662A5081491821 @default.
• W1508581662 hasAuthorship W1508581662A5084998888 @default.
• W1508581662 hasBestOaLocation W15085816621 @default.
• W1508581662 hasConcept C126322002 @default.
• W1508581662 hasConcept C127413603 @default.
• W1508581662 hasConcept C168563851 @default.
• W1508581662 hasConcept C17744445 @default.
• W1508581662 hasConcept C177713679 @default.
• W1508581662 hasConcept C194828623 @default.
• W1508581662 hasConcept C199539241 @default.

• next